BSX Downgraded To Conviction Sell At Goldman

Symbols: BSX
Tags: Goldman
Share

Analysts at Goldman Sachs downgrade Boston Scientific (NYSE: BSX) from "neutral" to "conviction sell." The target price for BSX is set to $6.

BSX’ gained 1.47% to trade at $6.90. More Analyst Ratings here


 
 
< Previous
Goldman Downgrades UNH To Buy
Next >
CYH Upgraded To Neutral
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust

Special Offers:
Quick Cash Advance